Therapeutics News and Research

RSS

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

PTC announces ataluren Phase 2b efficacy data at International Congress

PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.

18 Oct 2010

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

EntreMed receives letter from NASDAQ Stock Market

EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).

15 Oct 2010

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

Discovery Laboratories, Inc. today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has completed and the results from the study will be presented at the upcoming North American Cystic Fibrosis Conference (NACFC; October 21-23, 2010).

15 Oct 2010

GI Dynamics' EndoBarrier therapy to treat type 2 diabetes and obesity granted European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.

15 Oct 2010

DFG to establish new Research Units

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing four new Research Units to facilitate cross-regional, interdisciplinary cooperation among researchers. This decision was taken by the DFG Senate at its autumn meeting in Bonn. The new groups are intended to enable researchers to devote themselves to current and urgent issues within their fields and to develop new approaches.

15 Oct 2010

Enzo Biochem fiscal 2010 total revenues increase 8% to $97.1 million

Enzo Biochem, Inc. today reported results for the fiscal fourth quarter, consistent with our announcement on September 20, 2010, and for the year ended July 31, 2010.

15 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

Mary Lee's primary care physician is also a family friend. When he walked into the exam room in October 2006 with tears in his eyes, she knew something serious was wrong. But she was shocked to learn she had a brain tumor - and later found out it was the most aggressive malignant type, a glioblastoma multiforme.

14 Oct 2010

Top biopharma leaders to share strategies at Windhover's 2nd PharmAsia Summit

Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and The Pink Sheet, today announced the agenda for Windhover's 2nd PharmAsia Summit (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

14 Oct 2010

Metabolon announces publication of Ablation of Locus Coeruleus in Tg-2576 transgenic mice

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice" in the International Journal of Alzheimer Disease.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010